Compounds and compositions for treating dysproliferative diseases, and methods of use thereof
View Patent ↗Compounds are disclosed with activity towards killing dysproliferative cells in vitro and treating cancer in vivo. Cancers such as cancer of the colon, pancreas, prostate, lung, breast, urinary bladder, skin and liver are exemplary. Compounds, pharmaceutical compositions and methods of use are described.
1. A compound of Formula I
or a tautomer thereof, or a ester thereof;
wherein X 1 is selected from the group consisting of —O— and —NH—;
wherein X 2 is one or more substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, —NO 2 , —ONO 2 , —CN; an optionally substituted aliphatic, alicyclic, heteroalip hatic, aromatic, heterocyclic, heteroaromatic moiety; —OR R , —S(=O) n R d , —NR b R c , —C(=O)R a , and —C(=O)OR a , wherein n is 0-2, R R is an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, heteroaromatic or acyl moiety; R a , for each occurrence, is independently hydrogen or an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or a heteroaromatic moiety; R b and R c , for each occurrence, are independently selected from the group consisting of hydrogen; hydroxy; SO 2 R d ; aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, heteroaromatic or an acyl moiety; R d , for each occurrence, is independently selected from the group consisting of hydrogen; —N(R e ) 2 ; aliphatic, aryl and heteroaryl; and R e , for each occurrence, is independently hydrogen or aliphatic;
wherein A is
wherein R 2 is at least one halogen, X 2 is as defined above and R 3 and R 4 are independently hydrogen or an aliphatic group,
wherein D is hydroxyl; nitrate; halide; tosylate; phosphate; —OSO 2 NR x R y , where R x and R y are independently hydrogen, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, heteroaromatic or acyl moiety; —O—C 6 H 4 OC(═O)CH 3 ; an alkoxy moiety; an acyl moiety; or
where R 7 is hydrogen or one or more nitro groups;
with the proviso that the compound does not have the following structure
and that when X 1 is O and X 2 is H, D is not nitrate.
2. The compound of claim 1 wherein the compound is selected from the group consisting of:
and a meta-, ortho-, or para-isomer from among:
3. A composition comprising the compound of claim 1 and a carrier or excipient.
4. A compound of Formula I
or a tautomer thereof, or a ester thereof;
wherein X 1 is —NH—;
wherein X 2 is one or more substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, —NO 2 , —ONO 2 , —CN; an optionally substituted aliphatic, alicyclic, heteroaliphatic, aromatic, heterocyclic, heteroaromatic moiety; —OR R , —S(=O) n R d , —NR b R c , —C(=O)R a and —C(=O)OR a , wherein n is 0-2, R R is an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, heteroaromatic or acyl moiety; R a , for each occurrence, is independently hydrogen or an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or a heteroaromatic moiety; R b and R c , for each occurrence, are independently selected from the group consisting of hydrogen; hydroxy; SO 2 R d ; aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, heteroaromatic or an acyl moiety; R d , for each occurrence, is independently selected from the group consisting of hydrogen; —N(R e ) 2 ; aliphatic, aryl and heteroaryl; and R e , for each occurrence, is independently hydrogen or aliphatic;
wherein A is an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or heteroaromatic group;
wherein D is hydroxyl; halide; tosylate; phosphate; —OSO 2 NR x R y , where R x and R y are independently hydrogen, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, heteroaromatic or acyl moiety; —O—C 6 H 4 OC(═O)CH 3 ; an alkoxy moiety; an acyl moiety; or
where R 7 is hydrogen or one or more nitro groups.